Anti-Vaccinia Monoclonal Antibody

Technology IDE-123-2004-0
Anti-Vaccinia Monoclonal AntibodyLinked IDTAB-978InventorsJack Bennink (NIAID)Jonathan (Jon) Yewdell (NIAID)Josephine Cox (NIAID)Lead InventorsJonathan (Jon) Yewdell (NIAID)Co-InventorsJack Bennink (NIAID)Josephine Cox (NIAID)ApplicationsResearch MaterialsTherapeutic AreasInfectious DiseaseICsNIAIDThe current technology describes a monoclonal antibody that reacts with a vaccinia virus protein abundantly expressed under an early viral promoter after infection of cells. The antibody is useful for quantitating vaccinia virus infected cells and for studying the function of the protein to which it binds, which is known to be a double stranded RNA binding protein involved in resistance of the virus to interferons. This antibody is available for licensing through a biological materials license agreement.Request More InfoLicensing ContactBenjamin Edgar Hurley, [e-mail]: 240-669-5092Intellectual PropertiesEIR ApplicationResearch Material – Patent protection is not being pursued for this technologyPublicationsNuclear Localization of a Double-Stranded RNA-Binding Protein Encoded by the Vaccinia Virus E3L GeneCollaborationsLicensing DesiredDate PublishedWed, 09/01/2004 - 12:00Data SourcettsData Source IDE-123-2004-0

Source: NIH OTT Licensing Opportunities - July 21, 2021 Category: Research Authors: ott8admin Source Type: research